At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
MEDI2338 +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 1 clinical trial evaluating MEDI2338 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 31 participants across 4 sites in 2 countries.
Detailed Summary
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesSouth Africa, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionNov 2011
Study CompletionDec 2011
TodayJul 2026
First PostedMar 24, 2011
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.3 years ago
Interventions
MEDI2338biological
MEDI2338 single intravenous (IV) dose (lowest dose)
MEDI2338biological
MEDI2338 single IV dose (next highest dose)
MEDI2338biological
MEDI2338 single IV dose (next highest dose)
MEDI2338biological
MEDI2338 single IV dose (next highest dose)
MEDI2338biological
MEDI2338 single IV dose (highest dose)
Placeboother
Placebo single IV dose